We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA Sudoku: Math Puzzle Logic Used to Enhance Genome Sequencing Capability

By LabMedica International staff writers
Posted on 23 Jul 2009
A popular math-based game may now be poised to transform the fast-changing world of genome sequencing and the field of medical genetics, suggests a team of scientists. More...
Combining a 2,000-year-old Chinese math theorem with concepts from cryptology, the scientists have devised "DNA Sudoku.” The strategy allows tens of thousands of DNA samples to be combined, and their sequences--the order in which the letters of the DNA alphabet (A, T, G, and C) line up in the genome--to be determined all at once.

This achievement is in stark contrast to past applications that allowed only a single DNA sample to be sequenced at a time. It also significantly improves upon current approaches that, at best, can combine hundreds of samples for sequencing. "In theory, it is possible to use the Sudoku method to sequence more than a hundred thousand DNA samples,” said Cold Spring Harbor Laboratory (CSHL; Cold Spring Harbor, NY, USA) professor Gregory Hannon, Ph.D., a genomics expert, and leader of the team that invented the Sudoku approach. At that level of efficiency, it has the potential to greatly reduce costs. A sequencing project that costs upwards of US$10 million using conventional methods may be accomplished for $50,000 to $80,000 using DNA Sudoku, he estimated.

Originally devised to overcome a sequencing limitation that plagued one of the Hannon lab's research projects, the new method has tremendous potential for clinical applications. It can be utilized, according to Dr. Hannon, to analyze specific regions of the genomes of a large population and identify individuals who carry mutations that cause genetic diseases--a process known as genotyping.

The CSHL team has already begun to explore this possibility via collaboration with Dor Yeshorim (New York, NY, USA), an organization that has collected DNA from thousands of members of orthodox Jewish communities. The organization's aim is to prevent genetic diseases such as Tay-Sachs or cystic fibrosis that occur frequently within specific ethnic populations. The new method will now allow the many thousands of DNA samples gathered by Dor Yeshorim to be processed and sequenced in a single time-saving and cost-effective experiment, which should identify individuals who carry disease-causing mutations.

The mixing together and simultaneous sequencing of a massive number of DNA samples is known as multiplexing. In earlier multiplexing approaches, scientists first tagged each sample with a barcode--a short string of DNA letters known as oligonucleotides--before mixing it with other samples that also had unique tags. After the sample mix had been sequenced, scientists could use the barcode tags on the resulting sequences as identification markers and thus tell which sequence belonged to which sample.

"But this approach is very limiting,” explained Dr. Yaniv Erlich, a graduate student in the Hannon laboratory and first author on the article. "It's time-consuming and costly to have to design a unique barcode for each sample prior to sequencing, especially if the number of samples runs in the thousands.”

In order to circumvent this limitation, Dr. Erlich and others in the Hannon lab came up with the plan of mixing the samples in specific patterns, thereby creating pools of samples. Moreover, instead of tagging the individual samples within each pool, the scientists tagged each pool as a whole with one barcode. "Since we know which pool contains which samples, we can link a sequence to an individual sample with high confidence,” said Dr. Erlich.

The key to the researchers development is the pooling strategy, which is based on the 2,000-year-old Chinese remainder theorem. "It minimizes the number of pools and the amount of sequencing,” stated Dr. Hannon of their method, which they dubbed DNA Sudoku because of its similarity to the logic and combinatorial number-placement rules used in the popular game.

The technique, which the CSHL team has patented, is currently best suited for genotype analyses that require only short segments of an individual's genome to be sequenced to find out if the individual is carrying a specific variant of a gene or a rare mutation. But as sequencing technologies improve and researchers gain the ability to generate sequences for longer segments of the genome, Dr. Hannon foresees wider clinical applications for their method such as human leukocyte antigen (HLA) typing, already an important diagnostic tool for autoimmune diseases, cancer, and for predicting the risk of organ transplantation.

The report was published in the July 1, 2009, issue of the journal Genome Research.

Related Links:

Cold Spring Harbor Laboratory
Dor Yeshorim




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.